Testing a new PET tracer for cancer imaging
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new imaging tracer called TATE-RGD to see if it can better spot certain tumors when used with a standard PET/CT scan. If you have cancer, you may be able to help by getting two scans a week apart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cancer (any type) through a biopsy or other test.
- You are able to have two PET/CT scans—one with a new tracer called TATE-RGD and one with a standard tracer called FDG—within one week.
- You are not allergic to TATE-RGD.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
This trial uses a new radioactive tracer that attaches to a protein found on many solid tumors, allowing doctors to see tumors on a PET scan. It may help improve how tumors are detected and monitored.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.